Keryx Biopharmaceuticals Announces European Medicines Agency Validation Of Marketing Authorization Application For Zerenex™

NEW YORK, April 2, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced that the European Medicines Agency ("EMA") has determined that the Company's Marketing Authorization Application ("MAA") seeking the approval of Zerenex™ (ferric citrate coordination complex) as a treatment for hyperphosphatemia in patients with chronic kidney disease ("CKD"), including dialysis- and non-dialysis-dependent CKD, is valid. Validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process.

Help employers find you! Check out all the jobs and post your resume.